{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:58:46Z","timestamp":1784800726923,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12328-021-01585-2","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T14:02:30Z","timestamp":1641736950000},"page":"271-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The impact of emricasan on chronic liver diseases: current data"],"prefix":"10.1007","volume":"15","author":[{"given":"Vasileios","family":"Lekakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-582X","authenticated-orcid":false,"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,9]]},"reference":[{"key":"1585_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","volume":"125","author":"AE Feldstein","year":"2003","unstructured":"Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437\u201343.","journal-title":"Gastroenterology"},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/hep.1840380432","volume":"38","author":"M Dodig","year":"2003","unstructured":"Dodig M, Mullen KD. New mechanism of selective killing of activated hepatic stellate cells. Hepatology. 2003;38:1051\u20133.","journal-title":"Hepatology"},{"key":"1585_CR3","doi-asserted-by":"crossref","unstructured":"Malhi H, Gores GJ, Lemasters J. Liver cell death. Mol Pathol Liver Dis. 2011;5:373\u2013387.","DOI":"10.1007\/978-1-4419-7107-4_24"},{"key":"1585_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hep.21062","volume":"43","author":"H Malhi","year":"2006","unstructured":"Malhi H, Gores G, Lemasters J. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43:31\u201344.","journal-title":"Hepatology"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1126\/science.1190354","volume":"329","author":"T Hidvegi","year":"2010","unstructured":"Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329:229\u201332.","journal-title":"Science"},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"14376","DOI":"10.1073\/pnas.97.26.14376","volume":"97","author":"S Sperandio","year":"2000","unstructured":"Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci. 2000;97:14376\u201381.","journal-title":"Proc Natl Acad Sci"},{"key":"1585_CR7","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gut.2004.053850","volume":"54","author":"ME Guicciardi","year":"2005","unstructured":"Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005;54:1024\u201333.","journal-title":"Gut"},{"key":"1585_CR8","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.281.5381.1309","volume":"281","author":"DR Green","year":"1998","unstructured":"Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309\u201312.","journal-title":"Science"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","volume":"281","author":"A Ashkenazi","year":"1998","unstructured":"Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305\u20138.","journal-title":"Science"},{"key":"1585_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1146\/annurev.biochem.68.1.383","volume":"68","author":"WC Earnshaw","year":"1999","unstructured":"Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383\u2013424.","journal-title":"Annu Rev Biochem"},{"key":"1585_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1074-5521(98)90615-9","volume":"5","author":"NA Thornberry","year":"1998","unstructured":"Thornberry NA. Caspases: key mediators of apoptosis. Chem Biol. 1998;5:97\u2013103.","journal-title":"Chem Biol"},{"key":"1585_CR12","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1038\/onc.2008.297","volume":"27","author":"J Li","year":"2008","unstructured":"Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27:6194\u2013206.","journal-title":"Oncogene"},{"key":"1585_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2004.05.004","volume":"117","author":"F Martinon","year":"2004","unstructured":"Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell. 2004;117:561\u201374.","journal-title":"Cell"},{"key":"1585_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","volume":"68","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251\u2013306.","journal-title":"Int Rev Cytol"},{"key":"1585_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/jhep.2003.50002","volume":"37","author":"P Taimr","year":"2003","unstructured":"Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2\/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology. 2003;37:87\u201395.","journal-title":"Hepatology"},{"key":"1585_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/01.LAB.0000069036.63405.5C","volume":"83","author":"A Canbay","year":"2003","unstructured":"Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Investig. 2003;83:655\u201363.","journal-title":"Lab Investig"},{"key":"1585_CR17","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1124\/jpet.103.062034","volume":"309","author":"NC Hoglen","year":"2004","unstructured":"Hoglen NC, Chen LS, Fisher CD, et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004;309:634\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"1585_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5414\/CPP41441","volume":"41","author":"KL Valentino","year":"2003","unstructured":"Valentino KL, Gutierrez M, Sanchez R, et al. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther. 2003;41:441\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1585_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1254\/jphs.SC0070207","volume":"105","author":"Y Ueno","year":"2007","unstructured":"Ueno Y, Ohmi T, Yamamoto M, et al. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J Pharmacol Sci. 2007;105:201\u20135.","journal-title":"J Pharmacol Sci"},{"key":"1585_CR20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1124\/jpet.103.060129","volume":"308","author":"A Canbay","year":"2004","unstructured":"Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004;308:1191\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"1585_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2001-17555","volume":"21","author":"JJ Macher","year":"2001","unstructured":"Macher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis. 2001;21:417\u201326.","journal-title":"Semin Liver Dis"},{"key":"1585_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00109-018-1642-9","volume":"96","author":"A Eguchi","year":"2018","unstructured":"Eguchi A, Koyama Y, Wree A, et al. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. J Mol Med (Berl). 2018;96:575\u201383.","journal-title":"J Mol Med (Berl)"},{"key":"1585_CR23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep4.1360","volume":"3","author":"J Gracia-Sancho","year":"2019","unstructured":"Gracia-Sancho J, Manicardi N, Ortega-Ribera M, et al. Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism. Hepatol Commun. 2019;3:987\u20131000.","journal-title":"Hepatol Commun"},{"key":"1585_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/liv.12570","volume":"35","author":"FJ Barreyro","year":"2015","unstructured":"Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953\u201366.","journal-title":"Liver Int"},{"key":"1585_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou J, Huang N, Guo Y, et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm Sin B. 2019;9:526\u201336.","journal-title":"Acta Pharm Sin B"},{"key":"1585_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1053\/jlts.2003.50019","volume":"9","author":"S Natori","year":"2003","unstructured":"Natori S, Higuchi H, Contreras P, et al. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl. 2003;9:278\u201384.","journal-title":"Liver Transpl"},{"key":"1585_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/lt.21016","volume":"13","author":"NC Hoglen","year":"2007","unstructured":"Hoglen NC, Anselmo DM, Katori M, et al. A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl. 2007;13:361\u20136.","journal-title":"Liver Transpl"},{"key":"1585_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.yrtph.2015.04.007","volume":"72","author":"RH Elbekai","year":"2015","unstructured":"Elbekai RH, Paranjpe MG, Contreras PC, et al. Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice. Regul Toxicol Pharmacol. 2015;72:169\u201378.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1585_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/hep.21664","volume":"46","author":"PJ Pockros","year":"2007","unstructured":"Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46:324\u20139.","journal-title":"Hepatology"},{"key":"1585_CR30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1365-2036.2010.04264.x","volume":"31","author":"ML Shiffman","year":"2010","unstructured":"Shiffman ML, Pockros P, McHutchison JG, et al. Clinical trial: the efficacy and safety of oral PF-03491390, a pan-caspase inhibitor\u2014a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010;31:969\u201378.","journal-title":"Aliment Pharmacol Ther"},{"key":"1585_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt.15030","volume":"49","author":"M Shiffman","year":"2019","unstructured":"Shiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;49:64\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"1585_CR32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1\u2013F3 fibrosis. J Hepatol. 2020;72:816\u201327.","journal-title":"J Hepatol"},{"key":"1585_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/hep.30199","volume":"69","author":"G Garcia-Tsao","year":"2019","unstructured":"Garcia-Tsao G, Fuchs M, Shiffman M, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019;69:717\u201328.","journal-title":"Hepatology"},{"key":"1585_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","volume":"72","author":"G Garcia-Tsao","year":"2020","unstructured":"Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020;72:885\u201395.","journal-title":"J Hepatol"},{"key":"1585_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","volume":"17","author":"CT Frenette","year":"2019","unstructured":"Frenette CT, Morelli G, Shiffman ML, et al. Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo. Clin Gastroenterol Hepatol. 2019;17:774\u201383.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1585_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jceh.2017.11.006","volume":"8","author":"G Mehta","year":"2018","unstructured":"Mehta G, Rousell S, Burgess G, et al. A placebo-controlled, multicenter, double-blind, phase 2 randomized trial of the pan-caspase inhibitor emricasan in patients with acutely decompensated cirrhosis. J Clin Exp Hepatol. 2018;8:224\u201334.","journal-title":"J Clin Exp Hepatol"},{"key":"1585_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jhep.2020.09.029","volume":"74","author":"C Frenette","year":"2021","unstructured":"Frenette C, Kayali Z, Mena E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2021;74:274\u201382.","journal-title":"J Hepatol"},{"key":"1585_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-6143.2006.01595.x","volume":"7","author":"ES Baskin-Bey","year":"2007","unstructured":"Baskin-Bey ES, Washburn K, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant. 2007;7:218\u201325.","journal-title":"Am J Transplant"},{"key":"1585_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/lt.25934","volume":"27","author":"EM Weinberg","year":"2021","unstructured":"Weinberg EM, Curry MP, Frenette CT, et al. Multicenter, double-blind, randomized trial of emricasan in hepatitis C-treated liver transplant recipients with residual fibrosis or cirrhosis. Liver Transpl. 2021;27:568\u201379.","journal-title":"Liver Transpl"},{"key":"1585_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1126\/scitranslmed.aad3099","volume":"8","author":"G Brumatti","year":"2016","unstructured":"Brumatti G, Ma C, Lalaoui N, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2016;8:339\u201369.","journal-title":"Sci Transl Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01585-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T15:13:04Z","timestamp":1700061184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01585-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01585-2","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,9]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interests for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}